Introduction to Anaplastic Pleomorphic

The majority had glioblastoma (69%), followed by anaplastic pleomorphic xanthoastrocytoma and anaplastic astrocytoma (each 11%); of pts with known IDH/MGMT status, 3/29 pts had IDH1 mutations and 8/17 had MGMT promoter methylation.

The morphological variation of abnormal plasma cells in plasma cell neoplasms is vast, ranging from small lymphocyte-like cells to cleaved, convoluted, monocytoid or multilobated plasma cells to anaplastic pleomorphic large plasma cells, which have been reported previously.

Anaplastic pleomorphic lymphoid cells in pleural effusions are not common cytologic findings.

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare peripheral T-cell lymphoma composed of anaplastic pleomorphic T cells.

Background Anaplastic pleomorphic xanthoastrocytoma (APXA) is a rare subtype of CNS astrocytoma.

BRAFV600E mutation was documented in 6 (21%) tumors (4 gangliogliomas, 1 gangliocytoma, and 1 astrocytoma NOS resulted as anaplastic pleomorphic xanthoastrocytoma 8 years later).

Background: The survival rate of anaplastic pleomorphic xanthoastrocytoma (APXA) is not well established due to the limited number of cases, but a few reports have suggested that the 5-year overall survival rate for APXA patients isaround 50%.

Four organ transplant recipients from an organ donor diagnosed with anaplastic pleomorphic xanthoastrocytoma developed fatal malignancies for which the origin could not be confirmed by standard methods.

Tumor entities included three (n = 3) medulloblastomas, two (n = 2) pilocytic astrocytomas (PA), two (n = 2) anaplastic ependymomas and one (n = 1) diffuse astrocytoma, anaplastic astrocytoma (n = 1), pilomyxoid astrocytoma (n = 1) and anaplastic pleomorphic xanthoastrocytoma (n = 1).

Here, we report a rare case of anaplastic pleomorphic xanthoastrocytoma (PXA) associated with an H3G34 mutation.

Patients & results: Targeting BRAF V600E mutations with concurrent dabrafenib and trametinib in anaplastic pleomorphic xanthoastrocytoma resulted in a transient radiographic and clinical response and no therapeutic benefit in a patient with an epithelioid glioblastoma.

In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma (PXA) has been newly defined as a variant of the PXA entity.

To the Editor We present a patient with disseminated anaplastic pleomorphic xanthoastrocytoma (PXA) who developed subcutaneous masses with histologic features of fat necrosis while on vemurafenib, trametinib, and temozolomide.

The NRF1-BRAF fusion has only been reported in a single case of anaplastic pleomorphic xanthoastrocytoma, and BRAF rearrangement has never been reported in UC.

Immunohistochemistry confirmed the diagnosis of anaplastic pleomorphic xanthoastrocytoma (aPXA).

To the Editor: Anaplastic pleomorphic xanthoastrocytoma (PXA) was added to the 2016 WHO Classification of Central Nervous System Tumors to describe a neoplasm that is morphologically similar to grade II PXA, but with increasedmitotic activity and shorter survival.

In the present report we describe a BRAF V600E‐mutated tumor with divergent morphological appearance comprising of anaplastic pleomorphic xanthoastrocytoma and astroblastoma.

Epithelioid glioblastoma (EGBM) and anaplastic pleomorphic xanthoastrocytoma (APXA) are two rare entities with different prognoses.